From Laboratory Finding to Clinical Use

#A model is not the clinical outcome

A laboratory finding can suggest how a disease works or how an intervention might act. NCATS describes preclinical work using cells, animal models, tissue samples and computer-assisted simulations. These models help investigate an idea; they do not themselves establish what happens to patients in routine care.

For drug development, FDA describes preclinical assessment of dosing and toxicity before researchers decide whether testing in people should proceed. A promising biological effect is therefore a starting point for further questions about exposure, harm and useful outcomes, not proof that a treatment is ready.

Evidence: NCATS: translational science spectrum / FDA: preclinical drug research

#Human studies examine different uncertainties

FDA distinguishes preclinical information from clinical research in people. In drug trials, early work examines how the drug behaves in the body, dosing and acute harms. Later studies investigate treatment effects in a defined population and can reveal adverse effects missed by smaller or shorter studies. The study protocol, comparison and outcomes still matter more than a phase label alone.

Clinical research also includes observational, behavioural and health-services studies, as NCATS explains. The drug-development phase sequence is not a universal timetable for every device, diagnostic test or care practice. Translation can move back and forth as human findings raise new laboratory or practical questions.

Evidence: FDA: Clinical research and trial phases / NCATS: translational science spectrum

#A biological change needs a justified interpretation

A biomarker can measure a biological process or response without directly showing whether people feel better, function better or live longer. FDA distinguishes such measures from clinical outcomes. Some biomarkers become surrogate endpoints only after evidence supports their ability to predict a particular clinical benefit in a defined context.

A candidate surrogate remains under evaluation. FDA also describes reasonably likely surrogates used in accelerated drug approval with less support than a validated surrogate, making further evaluation important. Do not turn a laboratory measurement into a patient-benefit claim without checking its validation, the outcome and the context of use.

Evidence: FDA: Surrogate endpoint resources

#Authorization and routine use answer different questions

FDA's drug review assesses evidence for an intended use and develops prescribing information that describes the basis for approval and use of the drug. That is a defined regulatory decision, not an assessment of every possible application. This United States drug example should not be treated as the approval route for all products or countries.

NCATS distinguishes research from implementation in everyday care. Adoption raises questions about how useful interventions work across real settings, and implementation research can identify gaps and new questions. A result under study conditions does not explain every practical barrier, resource need or difference between populations.

Evidence: FDA: review of a drug for its intended use / NCATS: translational science spectrum

#Evidence continues after a product reaches care

FDA states that complete drug-safety information cannot be available at approval. Reports and further studies can reveal problems over months or years and lead to changes in cautions or use. Approval does not mean that harms are impossible or that the evidence has stopped developing.

NCATS describes translation as a connected spectrum rather than a guaranteed one-way journey. Findings in practice and at population level can inform new research. Read the current evidence and the relevant product information when interpreting a claim. This page is general research education, not a recommendation to start, stop or change any treatment.

Evidence: FDA: Post-market drug safety monitoring / NCATS: translational science spectrum

Source note

The sections above were checked against the linked sources. No clinical review has been performed. This is general research education, not a clinical guideline.